newsfilter
← Latest News
GlobeNewswire·

ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.

Refined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company's highest priority marketDiscontinued the ex-U.S.-based PROACT 2 trial and focused Company